A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Clinical trial NCT06268613 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06268613
Sponsor: Samsung Bioepis Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Stage II Non-small Cell Lung Cancer Stage IIIA

Start date: 2024-01-16
Primary completion: 2026-02-19
Enrollment: 163

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.